BioView to develop lung cancer test with Clarient

The test, which examines the patient's sputum, was first developed at the M.D. Anderson Cancer Center at the University of Texas.

BioView Ltd. (TASE:BIOV) has concluded a cooperation agreement with Clarient Inc. (Nasdaq: CLRT) for the development of a non-invasive diagnostic test for the early detection of non-small cell lung cancer (NSCLC). The test, which examines the patient's sputum, was first developed at the M.D. Anderson Cancer Center at the University of Texas. The test is expected to be administered for the early detection of lung cancer in smokers and other at-risk groups.

According to the National Institute of Cancer of Cancer in the US, lung cancer has the highest mortality rate of any cancer with 250,000 people diagnosed with the condition every year in the US alone where there are 160,000 fatalities annually. NSCLC is the most prevalent type of lung cancer, representing 85% of cases of the disease.

Rehovot-based BioView's innovative test is performed by DNA biomarkers developed at the M.D. Anderson Center. The company owns the exclusive license to the test.

BioView's share was down 0.52% to NIS 1.15 in early afternoon trading today. He share of Clarient, which is based in Aliso Viejo, California, closed on Monday at $2.37, giving a market cap of $185.87 million.

Published by Globes [online], Israel business news - www.globes-online.com - on December 15, 2009

© Copyright of Globes Publisher Itonut (1983) Ltd. 2009

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס